| abstract |
DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro-drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity n n n n n n n n n n wherein, for example, r is 0 or 1 and X 1 is linear (1-3C)alkyl; n q is 0 or 1 and X 2 is fluoro, chloro or (1-3C)alkyl; n Y 1 is selected from fluoro, chloro, bromo, cyano, (1-3C)alkyl and (1-2C)alkoxy; n n is 0, 1 or 2 and Y 2 is fluoro, chloro or (1-3C)alkyl; n p is 0, 1 or 2 and Y 3 is (1-3C)alkyl or forms a (3-5C)cycloalkyl ring; n Z is carboxy or —CONHSO 2 Me or —CONRbRc wherein Rb and Rc are independently selected, for example, from hydrogen and (1-4C)alkyl or Rb and Rc are linked so as to form a morpholine ring or a (4-6C)heterocyclic ring and when Z is —CONRbRc the Rb and Rc groups may be optionally substituted by carboxy. |